Clinical trial · Observational
Follow up After Cryoablation of Small Renal Masses.
Follow up After Percutaneous MR-guided Cryoablation of Small Renal Masses.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Currently there is no consensus on post procedural follow up imaging following percutaneous cryoablation of renal tumors. Interpretation of conventional contrast enhanced imaging (CT and MRI) during follow up can be very challenging. The objective of this study is to evaluate the feasibility of early evaluation of the therapeutic effect by performing early follow up imaging after percutaneous MR-guided cryoablation of pT1a renal cell carcinoma using 111In-Girentuximab-DOTA SPECT CT imaging.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Renal Cell | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 111In-Girentuximab DOTA SPECT | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 111In-Girentuximab DOTA SPECT
- description
- Patients \>50 years of age with renal tumours ≤4 cm highly suspicious for a malignancy planned to undergo cryotherapy will undergo 111In-Girentuximab DOTA SPECT scanning.
- interventionNames
- Other: 111In-Girentuximab DOTA SPECT
Primary outcomes (1)
- measure
- Predictive value.
- timeFrame
- Up to at least 3 months following initial treatment (cryoablation).
- description
- Positive predictive value and negative predictive value of 111In-Girentuximab-DOTA SPECT 4-6 weeks after intervention as confirmed on subsequent conventional follow up imaging (contrast enhanced MRI).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * \>50 years of age; * At least one untreated T1a tumour of one kidney (tumour ≤ 4 cm in greatest dimension); * Signed IRB-approved informed consent form. Exclusion Criteria: * Pregnancy or breast feeding; * Known hypersensitivity or HACA against Girentuximab. * Administration of experimental medication for imaging purposes within three months before administration of Indium-111-Girentuximab for this study, except the administration of Girentuximab labeled with a random isotope.
References
Publications (0)
Data not yet available